-- Clinical development of the MYC repressor APTO-253 will be discontinued --
-- Company will focus on advancing kinome inhibitor pipeline --
Read more at globenewswire.comAptose Provides Update on APTO-253 Program
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
